医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year

2018年01月23日 PM03:30
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global 100) for the third consecutive year. This distinction is based on 17 key performance indicators including financial management, clean revenue, and supplier performance. Takeda performed in the top 25% on innovation capacity, receiving notable recognition for its leadership diversity. Global 100 companies in 2018 represent the top 1.3% in the world on sustainability performance. The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos.

As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one of just ten pharmaceutical companies in the world to be listed.

“Takeda is honored to be recognized once again for our commitment to sustainability, particularly alongside such distinguished global corporations,” said Haruhiko Hirate, Corporate Communications & Public Affairs Officer. “We strive to create and maximize long-term economic, social, and environmental value worldwide, led by our unique and diverse corporate governance, through our corporate social responsibility (CSR), which contributes to the lasting health of patients worldwide through long-term investments in disease prevention, capacity building, and access to healthcare. As a company, Takeda strives for Better Health and a Brighter Future for people worldwide through leading innovation in medicine, together with the global community.”

In addition to the Global 100 Index, Takeda is recognized by multiple Socially Responsible Investment (SRI) valuations.

Name of Index/Investment
Universe/Ratings

 

Company/
Organization Conducting
Assessment

  Country   Honors Awarded
Dow Jones Sustainability Asia Pacific Index S&P Dow Jones Indices US 8th consecutive year
FTSE4Good Global Index FTSE Russel UK 13th consecutive year
Ethibel EXCELLENCE Investment Register Forum Ethibel BEL three times
Prime Status   Oekom   GER   first time
 

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TOKYO:4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

Additional information about Takeda is available through its Sustainable Value Report, https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180122005747/en/

CONTACT

Media Contacts:
Japanese Media
Takeda
Pharmaceutical Company Limited
Satoko Imai, +81-3-3278-2037
satoko.imai@takeda.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 新研究调查Masimo SpHb®在术后红细胞(RBC)输血最佳实践中的功用
  • 宝洁公司收购德国达姆施塔特默克集团的消费者健康业务
  • MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
  • Vaxart Announces $5 Million Inavir® Revenue Milestone
  • 和铂医药与科伦博泰开展全球合作,共同开发多个创新全人源抗体药物